Phase behavior and critical activated dynamics of limited-valence DNA nanostars

  • Silvia Biffi
    Department of Medical Biotechnology and Translational Medicine, Universitá degli Studi di Milano, I-20133 Milan, Italy;
  • Roberto Cerbino
    Department of Medical Biotechnology and Translational Medicine, Universitá degli Studi di Milano, I-20133 Milan, Italy;
  • Francesca Bomboi
    Department of Physics, Sapienza, Universitá di Roma, I-00185 Rome, Italy; and
  • Elvezia Maria Paraboschi
    Department of Medical Biotechnology and Translational Medicine, Universitá degli Studi di Milano, I-20133 Milan, Italy;
  • Rosanna Asselta
    Department of Medical Biotechnology and Translational Medicine, Universitá degli Studi di Milano, I-20133 Milan, Italy;
  • Francesco Sciortino
    Department of Physics, Sapienza, Universitá di Roma, I-00185 Rome, Italy; and
  • Tommaso Bellini
    Department of Medical Biotechnology and Translational Medicine, Universitá degli Studi di Milano, I-20133 Milan, Italy;

書誌事項

公開日
2013-09-09
DOI
  • 10.1073/pnas.1304632110
公開者
National Academy of Sciences

この論文をさがす

説明

<jats:title>Significance</jats:title> <jats:p>At atomic and molecular levels, particles interact via the immutable laws of quantum mechanics, whereas at nanoscopic and microscopic levels, interactions between colloidal particles can be determined by human design. We exploit DNA self-assembly to produce nanoscopic particles with a controlled number of interacting terminations, providing the particles with valence. Experimental investigation of the collective behavior of such colloids shows that reducing the number of interacting sites results in a significant shrinkage of the gas–liquid coexistence region, with critical parameters decreasing as the valence is reduced. We also observe an unconventional dynamic behavior in the proximity of the critical point. Such findings are relevant to answer fundamental physics issues and potentially to determine the stability region of new DNA-based materials.</jats:p>

収録刊行物

被引用文献 (12)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ